Pharmacotherapeutic group
Cytokines

Indications:
Treatment of patients with multiple sclerosis. RebifO decreases the frequency and severity of relapses and slows the progression of disability.
Treatment of patients with relapsing-remitting multiple sclerosis characterized by at least 2 recurrent attacks of neurological dysfunction (relapses) over the preceding 2-year period.

Rebif decreases the frequency and severity of relapses over 2 years.

Rebif 22 mcg/0,5 ml
Registration status: 328/07-300200000; expiry date: 21.08.2012
Dosage: 22 mcg/0,5 ml
Packaging: 3 pre-filled syringes
Shelf-life (months): 24 (t +2 - +8 C)

Rebif 44 mcg/0,5 ml
Registration status: 328/07-300200000; expiry date: 21.08.2012
Dosage: mcg/0,5 ml
Packaging: 3 pre-filled syringes
Shelf-life (months): 24 (t +2 - +8 C)